RNAZTranscode Therapeutics, Inc.

Nasdaq transcodetherapeutics.com


$ 1.27 $ -0.01 (-0.78 %)    

Wednesday, 12-Jun-2024 12:33:30 EDT
QQQ $ 474.44 $ -0.72 (-0.15 %)
DIA $ 388.67 $ -0.61 (-0.16 %)
SPY $ 542.59 $ -0.63 (-0.12 %)
TLT $ 93.53 $ 0.26 (0.27 %)
GLD $ 216.18 $ 0.72 (0.33 %)
$ 1.33
$ 1.28
$ 0.00 x 0
$ 0.00 x 0
$ 1.27 - $ 1.28
$ 0.42 - $ 128.00
413,213
na
6.84M
$ -65.98
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-16-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-15-2021 09-30-2021 10-Q
12 08-23-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 transcode-therapeutics-has-regained-compliance-with-nasdaqs-continued-listing-requirements

TransCode Therapeutics, Inc. (NASDAQ:RNAZ), (the "Company"), an RNA oncology company committed to more effectively trea...

 transcode-therapeutics-regains-compliance-with-minimum-bid-price-requirement-per-nasdaq-listing-rule-5550a2

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 hc-wainwright--co-reiterates-buy-on-transcode-therapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Emily Bodnar reiterates TransCode Therapeutics (NASDAQ:RNAZ) with a Buy and maintains $3 pri...

 why-transcode-therapeutics-rnaz-stock-is-getting-hammered

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potenti...

 transcode-therapeutics-earlier-issued-open-letter-to-shareholders-asks-shareholders-to-give-co-authorization-to-effect-a-reverse-stock-split-as-a-last-resort-incase-the-nasdaq-panel-hearing-recommends-shares-to-be-delisted

The Board and Management of TransCode Therapeutics (NASDAQ:RNAZ) today issued the following open letter to shareholders of the ...